Pharmacosmos predicts record financial year after launches in US and China
The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Pharmacosmos has lit a fire under its dream of becoming an international company by establishing a presence in the US and China through subsidiaries and launching its main product (called Monoferric in the US and Monofer in China) on both markets.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos launches cell therapy market offensive
For subscribers
